Natera (NASDAQ:NTRA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Natera (NASDAQ:NTRA) released its earnings results on Thursday. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01, Zacks reports. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera updated its FY 2025 guidance to EPS.

Natera Trading Down 2.5 %

Natera stock opened at $156.61 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $167.59 and a two-hundred day moving average price of $146.60. The firm has a market capitalization of $20.68 billion, a price-to-earnings ratio of -88.98 and a beta of 1.66. Natera has a 52-week low of $75.18 and a 52-week high of $183.00.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Piper Sandler boosted their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Craig Hallum boosted their price objective on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.94.

Insider Buying and Selling at Natera

In other news, insider John Fesko sold 663 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 43,502 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the completion of the sale, the chief financial officer now directly owns 70,629 shares of the company’s stock, valued at approximately $12,492,857.52. This represents a 38.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 295,772 shares of company stock valued at $49,741,699 in the last ninety days. Company insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.